Stock Plans and Stock Based Compensation

12 Months Ended

Dec. 31, 2019

Share-based Payment Arrangement [Abstract]

Stock Plans and Stock Based Compensation

In 2019, the 2009 Tompkins Financial Corporation Equity Plan (“2009 Equity Plan”) expired and was replaced by the new Tompkins Financial Corporation 2019 Equity Plan (“2019 Equity Plan”). Under the 2019 Equity Plan, the Company may grant stock appreciation rights ("SARs"), shares of restricted stock and restricted units and performance share awards covering up to 1,275,000 shares of the Company's common stock to certain officers, employees, and nonemployee directors. Additionally, restricted stock awards and restricted units and performance share awards will reduce the shares available for grant under the 2019 Equity Plan by 4.25 shares for each share subject to an award, resulting in a total number of full-value share awards that may be issued under the 2019 Plan to 300,000. Stock options and SARs are granted at an exercise price equal to the stock’s fair value at the date of grant, may not have a term in excess of ten years, and have vesting periods that range between five and seven years from the grant date. Restricted stock awards have vesting periods that range between five and seven years, and restricted units vest in five years from grant date, and have grant date fair values that equal the closing price of the Company’s common stock on grant date. Prior to the adoption of the 2009 Equity Plan, the Company had similar stock option plans, which remain in effect solely with respect to unexercised options issued under these plans.

The Company granted 62,360 equity awards to its employees in 2019, consisting of 49,365 shares of restricted stock, 4,650 performance share awards and 8,345 restricted stock units. The Company granted 65,785 equity awards to its employees in 2018, consisting of 65,785 shares of restricted stock. The Company granted 59,333 equity awards to its employees in 2017, consisting of 59,333 shares of restricted stock.

The following table presents the activity related to stock options and SARs under all plans for the year ended December 31, 2019.



	Number of Shares/Rights		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at January 1, 2019	225,375		$	48.02
Granted	0		0.00
Exercised	(64,865	)	43.41
Forfeited	(2,888	)	58.91
Outstanding at December 31, 2019	157,622		$	49.72	4.34	$	6,585,638
Exercisable at December 31, 2019	103,927		$	46.91	3.83	$	4,634,146

Total stock-based compensation expense for stock options and SARs was $235,000 in 2019, $304,000 in 2018, and $367,000 in 2017. As of December 31, 2019, unrecognized compensation cost related to unvested stock options and SARs totaled $375,000. The cost is expected to be recognized over a weighted average period of 2.2 years. Net cash proceeds, tax benefits and intrinsic value related to total stock options, SARs, and restricted stock exercised is as follows:



(in thousands)	2019			2018			2017
Proceeds from stock option exercises	$	(992	)	$	(540	)	$	(641	)
Tax benefits related to stock option exercises	944			680			1,634
Intrinsic value of stock option exercises	2,460			1,447			3,139

The Company uses the Black-Scholes option-valuation model to determine the fair value of incentive stock options and SARs at the date of grant. The valuation model estimates fair value based on the assumptions listed in the table below. The risk-free rate is the interest rate available on zero-coupon U.S. Treasury instruments with a remaining term equal to the expected term of the share option at the time of grant. The expected dividend yield is based on the dividend trends and the market price of the Company’s stock price at grant. Volatility is largely based on historical volatility of the Company’s stock price. The expected term is based upon historical experience of employee exercises and terminations as the vesting term of the grants. The fair values of the grants are expensed over the vesting periods. There were no stock options or SARs granted in 2019, 2018 and 2017.



December 31, 2019
Options and SARs Outstanding			Options and SARs Exercisable
Range of Exercise Prices	Number Outstanding	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price
$35.71-37.50	31,680	1.62	$	37.00	31,680	$	37.00
$37.51-41.00	28,155	3.28	$	40.60	21,500	$	40.60
$41.01-50.00	47,195	4.86	$	49.22	28,226	$	49.22
$50.01-76.90	50,370	6.15	$	63.12	22,410	$	63.87
$76.91-86.18	222	6.89	$	86.18	111	$	86.18
	157,622	4.34	$	49.72	103,927	$	46.91

The following table presents activity related to restricted stock awards for the twelve months ended December 31, 2019.



	Number of Shares		Weighted Average Fair Value
Unvested at January 1, 2019	255,239		$	66.52
Granted	62,360		89.21
Vested	(61,275	)	60.48
Forfeited	(8,357	)	70.62
Unvested at December 31, 2019	247,967		$	73.66

The Company granted 49,365 restricted stock awards, 8,345 restricted stock units and 4,650 performance share awards in 2019, each at an average grant date fair value of $89.21. The Company granted 65,785 restricted stock awards in 2018 at an average grant date fair value of $75.44. The Company granted 59,333 restricted stock awards in 2017 at an average grant date fair value of $79.51. The grant date fair values were the closing prices of the Company’s common stock on the grant dates. The Company recognized stock-based compensation related to restricted stock awards, restricted stock units, and performance share awards of $4.0 million in 2019, $3.2 million in 2018, and $2.6 million in 2017. Unrecognized compensation costs related to restricted stock and performance awards, and restricted stock units totaled $14.1 million at December 31, 2019 and will be recognized over 3.5 years and 4.9 years, respectively on a weighted average basis.